These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1084 related articles for article (PubMed ID: 16050785)

  • 41. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
    Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
    Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is EGFR really a therapeutic target in head and neck cancers?
    Agarwal V; Subash A; Nayar RC; Rao V
    J Surg Oncol; 2019 May; 119(6):685-686. PubMed ID: 30701564
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
    Cohen EE; Davis DW; Karrison TG; Seiwert TY; Wong SJ; Nattam S; Kozloff MF; Clark JI; Yan DH; Liu W; Pierce C; Dancey JE; Stenson K; Blair E; Dekker A; Vokes EE
    Lancet Oncol; 2009 Mar; 10(3):247-57. PubMed ID: 19201650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma.
    Oliveira-Silva RJ; Carolina de Carvalho A; de Souza Viana L; Carvalho AL; Reis RM
    Recent Pat Anticancer Drug Discov; 2016; 11(2):170-83. PubMed ID: 26955963
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Khuri FR
    Head Neck; 2013 Mar; 35(3):443-53. PubMed ID: 22052826
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors.
    Ahmed SM; Cohen EE
    Curr Cancer Drug Targets; 2007 Nov; 7(7):666-73. PubMed ID: 18045071
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of advanced head and neck cancer with cetuximab.
    Merlano M; Garrone O
    Int J Biol Markers; 2007; 22(1 Suppl 4):S71-6. PubMed ID: 17520584
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
    Tinhofer I; Klinghammer K; Weichert W; Knödler M; Stenzinger A; Gauler T; Budach V; Keilholz U
    Clin Cancer Res; 2011 Aug; 17(15):5197-204. PubMed ID: 21653686
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer.
    López-Albaitero A; Ferris RL
    Arch Otolaryngol Head Neck Surg; 2007 Dec; 133(12):1277-81. PubMed ID: 18086972
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
    Ansell A; Jedlinski A; Johansson AC; Roberg K
    J Oral Pathol Med; 2016 Jan; 45(1):9-16. PubMed ID: 25677871
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
    Kondo N; Tsukuda M; Taguchi T; Nakazaki K; Sakakibara A; Takahashi H; Toth G; Nishimura G
    Cancer Sci; 2011 Sep; 102(9):1717-23. PubMed ID: 21631644
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Role of targeted therapy in the treatment of squamous cell head and neck cancer].
    Gyergyay F
    Magy Onkol; 2007; 51(2):155-7. PubMed ID: 17660872
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.
    Vermorken JB; Herbst RS; Leon X; Amellal N; Baselga J
    Cancer; 2008 Jun; 112(12):2710-9. PubMed ID: 18481809
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of Cetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck.
    Li JZ; Zheng JW; Zhang ZY
    Shanghai Kou Qiang Yi Xue; 2008 Feb; 17(1):1-5. PubMed ID: 18360658
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
    Karamouzis MV; Grandis JR; Argiris A
    JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
    Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
    Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.